10-K: Merit Medical Systems Reports Strong 2025 Growth

Merit Medical Systems, Inc. reported robust financial results for the fiscal year ended December 31, 2025, with significant revenue growth and increased profitability driven by strategic acquisitions and strong demand.

Summary

• Net sales increased 11.8% to $1.516 billion in 2025, up from $1.357 billion in 2024.
• Gross profit as a percentage of sales improved to 48.7% in 2025 from 47.4% in 2024.
• Net income rose to $128.5 million ($2.13 per diluted share) in 2025, compared to $120.4 million ($2.03 per diluted share) in 2024.
• Cardiovascular segment sales grew 10.9% to $1.443 billion in 2025.
• Endoscopy segment sales surged 33.0% to $72.9 million in 2025.
• U.S. sales increased 13.6% to $909.5 million, representing 60.0% of net sales in 2025.
• International sales grew 9.1% to $606.4 million, accounting for 40.0% of net sales in 2025.
• Completed acquisitions of Biolife, L.L.C. in May 2025 and the C2 CryoBalloon device from Pentax of America, Inc. in November 2025.
• Cash provided by operating activities increased by $76.6 million to $297.4 million in 2025.
• Capital expenditures for property and equipment were $81.7 million in 2025.
• The Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG) formally concluded on January 23, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, demonstrating solid growth in sales and profitability, effective integration of acquisitions, and a commitment to innovation and sustainability, despite facing geopolitical and competitive headwinds.

Positives

• Net sales grew by a strong 11.8% to $1.516 billion in 2025.
• Gross profit margin improved to 48.7% in 2025, indicating enhanced profitability.
• Net income increased by 6.7% to $128.5 million, with diluted EPS rising to $2.13.
• The Endoscopy segment showed significant growth of 33.0% in sales.
• Cash flow from operating activities increased substantially by $76.6 million to $297.4 million.
• Successfully integrated recent acquisitions, including Biolife, L.L.C. and the C2 CryoBalloon device.
• The Corporate Integrity Agreement (CIA) with the OIG was formally completed in January 2026, removing a significant compliance oversight.
• No material security breaches were experienced in the last three years, demonstrating strong cybersecurity measures.
• Achieved ISO 14001 certification at nine facilities and ISO 45001 certification at eight manufacturing facilities and one distribution facility, highlighting commitment to environmental and occupational health standards.
• Maintained zero healthcare plan cost increases for U.S. employees for the tenth consecutive year.
• Employee engagement survey participation reached a high of 93% in 2025, indicating a positive internal culture.
• The China subsidiary was recognized as a China Top Employer for five consecutive years.

Negatives

• Selling, general and administrative (SG&A) expenses increased by 13.9% to $455.2 million in 2025.
• Research and development (R&D) expenses increased by 11.3% to $97.4 million in 2025.
• Other expense, net, increased to $13.8 million in 2025 from $5.7 million in 2024, primarily due to decreased interest income.
• The effective income tax rate increased to 24.8% in 2025 from 19.8% in 2024.
• Negative impacts from China's volume-based procurement (VBP) policy on product pricing and revenue have persisted since 2022 and are expected to continue in 2026.
• Inventory levels increased by $21.6 million in 2025, partly due to a strategy to build bridge inventory for production line transfers and increases in safety stock due to vendor supply delays.
• Foreign currency exchange rate fluctuations negatively impacted net sales by $(7.2) million in 2024 and $(6.4) million in 2023, although it had a positive impact of $5.2 million in 2025.

Risks

• Disruptions in the supply from third-party vendors of materials and components, including sterilization services, could lead to product shortages and price increases.
• Cost volatility, particularly for raw materials like resins, transportation, and labor, may adversely affect operations and profitability if not offset by price increases or cost reductions.
• Changes in economic and geopolitical conditions, domestic and foreign trade policies (e.g., tariffs), and monetary policies could increase manufacturing costs, disrupt supply chains, and reduce demand.
• Damage or interruption to operations, facilities, manufacturing processes, or information technology systems due to natural disasters, cyber-attacks, or geopolitical disruptions could adversely affect business.
• Consolidation in the healthcare industry, group purchasing organizations, and public cost-containment measures (like China's VBP policy) lead to demands for price concessions, reducing revenues and margins.
• Inability to compete in markets due to rapid technological change, new market entrants, or failure to adapt to emerging technologies such as artificial intelligence (AI).
• Substantial costs and integration challenges associated with evaluating, negotiating, and closing acquisitions, and failure to realize anticipated benefits from acquired businesses.
• Inability to accurately forecast customer demand for products and manage inventory effectively, potentially leading to write-downs or inability to meet order requirements.
• Reliance on third-party distributors in many countries exposes the company to commercial, legal, compliance, and reputational risks.
• Failure to effectively execute leadership succession plans and attract, develop, and retain key employees could harm business or results of operations.
• The extensive and dynamic FDA regulatory clearance process, and foreign regulatory approvals (e.g., EU MDR), may lead to delays, increased expenses, or product discontinuation.
• Unsuccessful preand post-market clinical trials relating to products could have a material adverse effect on prospects.
• The medical device industry is subject to extensive scrutiny and regulation by governmental authorities, and violations could result in significant penalties.
• Laws targeting fraud and abuse in the healthcare industry (e.g., Anti-Kickback Statute, False Claims Act) could lead to investigations, fines, and exclusion from federal programs.
• Failure to comply with the U.S. Foreign Corrupt Practices Act and similar anti-bribery laws in non-U.S. jurisdictions could result in civil and criminal penalties.
• Limits on reimbursement imposed by governmental and other programs may adversely affect customer purchasing decisions.
• Evolving domestic and foreign laws and regulations regarding privacy and data protection (e.g., HIPAA, GDPR, PIPL) could result in claims, penalties, and increased operational costs.
• Use of products in unapproved circumstances could expose the company to liabilities and regulatory actions.
• Products may be subject to product liability claims and warranty claims, potentially leading to significant costs, recalls, or reputational harm.
• Misconduct by employees, independent contractors, consultants, manufacturers, and distributors could lead to regulatory actions or lawsuits.
• Routine involvement in litigation, including product liability, intellectual property, and regulatory compliance matters, could affect financial condition and results of operations.
• Changes in tax laws, fluctuations in tax rates, or exposure to additional tax liabilities (e.g., OECD Pillar Two, U.S. budget reconciliation package) may adversely affect the effective tax rate.
• Failure to comply with applicable environmental, health, and safety laws and regulations (e.g., PFAS, Ethylene Oxide use) could negatively affect business.
• Negative impacts from corporate social responsibility (CSR) laws, regulations, practices, and evolving stakeholder expectations.
• Risks related to climate change, including increased frequency and severity of natural disasters, could cause business and supply chain interruptions.
• Inability to protect intellectual property (patents, trade secrets, trademarks) could harm business and financial condition.
• Claims by third parties that the company infringes their intellectual property rights could lead to costly litigation or licensing expenses.
• Reliance on information technology systems, with risks of material disruption or security breaches, could adversely affect business, reputation, or financial condition.
• Agreements and instruments governing debt contain restrictions and limitations that could significantly affect the ability to operate and liquidity.
• Inability to service all indebtedness if cash flow is insufficient or additional liquidity sources are inaccessible.
• The fundamental change repurchase feature of the Convertible Notes may delay or prevent an otherwise beneficial attempt to acquire the company.
• The market price of common stock has been and may continue to be volatile.
• Fluctuations in foreign currency exchange rates may negatively impact financial results.

Future Outlook

Merit Medical Systems anticipates continued negative impacts from China's volume-based procurement (VBP) policy on revenue in 2026. The company expects to spend approximately $80 million to $100 million in 2026 for property and equipment, including a new distribution facility in South Jordan, Utah. It plans to continue implementing its eWorq program globally, aiming for 93% adoption by the end of 2026. The company is also preparing to comply with the European Union's Medical Device Regulation (MDR) before transitional periods expire in December 2027 or 2028, though some products may be discontinued or postponed in the E.U. Merit Medical Systems expects to continue utilizing AI in its operations and pursuing new AI technology partnerships. Management believes existing cash balances, anticipated future cash flows from operations, and borrowings under long-term debt agreements will be adequate to fund current and planned future operations for the foreseeable future.

Management Comments

• "We believe that long-term value is created for our customers, employees, shareholders, and communities when we focus outward and are determined to deliver an exceptional customer experience."
• "We believe the classified board provision will help to assure the continuity and stability of our Board of Directors and the business strategies and policies of our company as determined by the Board of Directors."
• "We expect the Control Shares Act to have an anti-takeover effect with respect to transactions not approved in advance by our Board of Directors. The Control Shares Act may also discourage takeover attempts that might result in a premium over the market price for the shares of common stock held by our shareholders."
• "We intend to continue our compliance program with continual improvements tailored to the nature of our medical device business."
• "We currently believe that our existing cash balances, anticipated future cash flows from operations and borrowings under our long-term debt agreements will be adequate to fund our current and currently planned future operations for the next twelve months and the foreseeable future."

Industry Context

StockSavvy.ai notes that Merit Medical Systems operates in a complex, highly competitive, and rapidly evolving global medical technology marketplace, characterized by continuous technological advancement, industry consolidation, and persistent demands for price reductions. The company's strategic focus on research and development, coupled with recent acquisitions in high-growth areas like endoscopy and interventional oncology, aligns with broader industry trends emphasizing innovation and market expansion. However, the ongoing negative impact of China's volume-based procurement (VBP) policy reflects a significant challenge faced by many medical device manufacturers globally due to governmental cost-containment initiatives. Merit Medical Systems' commitment to sustainability and employee well-being also positions it favorably amidst increasing industry and stakeholder focus on environmental, social, and governance (ESG) factors.

Comparison to Industry Standards

• Merit Medical Systems is a leading provider of digital inflation technology globally.
• The company is a market leader in the U.S. for analog inflation devices, control syringes, radar localization, waste-disposal systems, embolic beads, tubing, and manifolds.
• Merit Medical Systems competes with major medical device companies such as Teleflex Incorporated, Cook Medical Incorporated, Medtronic plc, Boston Scientific Corporation, Becton, Dickinson and Company (BD), Abbott Laboratories, Terumo Corporation, Edwards Lifesciences Corporation, Stryker Corporation, Johnson & Johnson, Getinge AB, and Olympus Corporation.
• The company also faces competition from domestic medical device companies in key international markets like China and Japan.

Management Changes

Corporate Governance

Legal Proceedings

• SEC Inquiry: The SEC's Division of Enforcement concluded its inquiry into the company's business activities in China, including interactions with hospitals and healthcare officials, and notified the company in Q3 2025 that no enforcement action was being recommended.
• General Litigation: The company is routinely involved in various claims and litigation matters, including product liability, intellectual property, contract disputes, and employment matters. Management believes no current legal proceedings, individually or in the aggregate, could have a material adverse effect on the company's financial position, results of operations, or cash flows.

Related Party Transactions

• During 2023, a former Merit director, who was also a former shareholder of Cianna Medical, received $0.9 million as a final contingent payment for the achievement of sales milestones specified in the 2018 merger agreement with Cianna Medical.

Stakeholder Impact

• Shareholders: Positive financial results (revenue, profit, EPS growth) and the resolution of the SEC inquiry are favorable. However, anti-takeover provisions in charter documents and Utah law could limit shareholders' ability to influence control changes or realize takeover premiums. Stock price volatility remains a risk.
• Employees: The company continues to invest in its people through competitive compensation and benefits, wellness programs, and talent development initiatives. High employee engagement is reported. The recent CEO transition could introduce temporary disruptions.
• Customers: The company's focus on innovation and a diverse product range aims to meet customer needs. However, customers may face pressure for price concessions due to healthcare industry consolidation and cost-containment measures, which could indirectly affect product availability or pricing.
• Suppliers: Reliance on third-party vendors for raw materials and sterilization services exposes the company to supply chain risks, including potential shortages and price increases.
• Creditors: The company's debt agreements contain restrictive covenants that could affect its ability to operate and its liquidity, requiring careful management of financial ratios and obligations.

Next Steps

• Continue to develop and launch innovative products to support clinical trends and address the increasing demands of target markets.
• Implement the eWorq program at manufacturing facilities globally to eliminate paper, with a goal of 93% adoption by the end of 2026.
• Obtain MDR approvals for principal products sold in the E.U. ahead of transition deadlines (December 31, 2027, or December 31, 2028, depending on risk classification).
• Continue to evaluate the full impact of the U.S. budget reconciliation package (OBBBA) and OECD Pillar Two global minimum tax rules.
• Fred P. Lampropoulos will provide consulting services to Merit Medical Systems until March 31, 2026.
• Merit Medical Systems is obligated to perform certain manufacturing, transition, and distribution services to Health Line International Corporation for a period of up to 24 months following the closing of the Dual Cap product line sale on February 17, 2026.

Key Dates

Recommendation

Merit Medical Systems demonstrated strong financial performance in 2025, marked by significant revenue growth, improved gross margins, and increased net income. The successful integration of recent acquisitions and the formal conclusion of the SEC inquiry remove potential uncertainties. While the company faces ongoing challenges from China's VBP policy and general industry competition, its strategic focus on innovation, operational efficiency, and commitment to sustainability positions it well for continued growth. The robust cash flow from operations further strengthens its financial health, making it an attractive investment for seasoned investors.

Keywords

Medical Devices, Interventional Cardiology, Radiology, Oncology, Endoscopy, SEC Filing, 10-K, Financial Results, Acquisitions, Corporate Governance, Risk Factors, Supply Chain, Regulatory Compliance, Cybersecurity, MMSI, Healthcare Technology, Profitability, Revenue Growth, International Sales, Capital Expenditures